Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines

• Viral lineages that escape antibodies have changed the landscape of the pandemic. • SARS-CoV-2 specific T cells effectively protect against disease development. • Vaccine efficacy should be evaluated by its ability to protect from severe disease. • Inactivated SARS-CoV-2 vaccine induces a multi-pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Anthony T., Lim, Joey Ming Er, Bertoletti, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wuhan Institute of Virology, Chinese Academy of Sciences 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639404/
https://www.ncbi.nlm.nih.gov/pubmed/36356859
http://dx.doi.org/10.1016/j.virs.2022.11.002
_version_ 1784825631835422720
author Tan, Anthony T.
Lim, Joey Ming Er
Bertoletti, Antonio
author_facet Tan, Anthony T.
Lim, Joey Ming Er
Bertoletti, Antonio
author_sort Tan, Anthony T.
collection PubMed
description • Viral lineages that escape antibodies have changed the landscape of the pandemic. • SARS-CoV-2 specific T cells effectively protect against disease development. • Vaccine efficacy should be evaluated by its ability to protect from severe disease. • Inactivated SARS-CoV-2 vaccine induces a multi-protein specific T cell response. • The superior breadth of the vaccine T cell response could be a protective asset.
format Online
Article
Text
id pubmed-9639404
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wuhan Institute of Virology, Chinese Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-96394042022-11-14 Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines Tan, Anthony T. Lim, Joey Ming Er Bertoletti, Antonio Virol Sin Perspective • Viral lineages that escape antibodies have changed the landscape of the pandemic. • SARS-CoV-2 specific T cells effectively protect against disease development. • Vaccine efficacy should be evaluated by its ability to protect from severe disease. • Inactivated SARS-CoV-2 vaccine induces a multi-protein specific T cell response. • The superior breadth of the vaccine T cell response could be a protective asset. Wuhan Institute of Virology, Chinese Academy of Sciences 2022-11-07 /pmc/articles/PMC9639404/ /pubmed/36356859 http://dx.doi.org/10.1016/j.virs.2022.11.002 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Perspective
Tan, Anthony T.
Lim, Joey Ming Er
Bertoletti, Antonio
Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
title Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
title_full Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
title_fullStr Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
title_full_unstemmed Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
title_short Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
title_sort protection from infection or disease? re-evaluating the broad immunogenicity of inactivated sars-cov-2 vaccines
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639404/
https://www.ncbi.nlm.nih.gov/pubmed/36356859
http://dx.doi.org/10.1016/j.virs.2022.11.002
work_keys_str_mv AT tananthonyt protectionfrominfectionordiseasereevaluatingthebroadimmunogenicityofinactivatedsarscov2vaccines
AT limjoeyminger protectionfrominfectionordiseasereevaluatingthebroadimmunogenicityofinactivatedsarscov2vaccines
AT bertolettiantonio protectionfrominfectionordiseasereevaluatingthebroadimmunogenicityofinactivatedsarscov2vaccines

Ejemplares similares